{"id":"NCT01152190","sponsor":"Eli Lilly and Company","briefTitle":"A Study in Benign Prostatic Hyperplasia","officialTitle":"A Randomized, Double Blind, Placebo-controlled Study to Evaluate the Effect of Tadalafil Once Daily for 8 Weeks on Prostatic Blood Flow and Perfusion Parameters in Men With Signs and Symptoms of Benign Prostatic Hyperplasia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-09","primaryCompletion":"2012-07","completion":"2012-07","firstPosted":"2010-06-29","resultsPosted":"2013-05-20","lastUpdate":"2013-05-20"},"enrollment":97,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"BASIC_SCIENCE"},"conditions":["Benign Prostatic Hyperplasia"],"interventions":[{"type":"DRUG","name":"Tadalafil","otherNames":["Cialis","LY450190"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"5 milligrams (mg) Tadalafil","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this trial is to evaluate the effect of tadalafil 5 milligrams (mg) daily for 8 weeks compared to placebo on prostatic blood perfusion in men with signs and symptoms of Benign Prostatic Hyperplasia (BPH), measured by resistive index (RI) in the prostate transition zone.","primaryOutcome":{"measure":"Change From Baseline to 8-Week Endpoint in Arterial Resistive Index (RI) in the Prostate Transition Zone","timeFrame":"Baseline, Week 8","effectByArm":[{"arm":"Placebo","deltaMin":-0.01,"sd":0.006},{"arm":"Tadalafil","deltaMin":0,"sd":0.006}],"pValues":[{"comp":"OG000 vs OG001","p":"0.121"}]},"eligibility":{"minAge":"45 Years","sex":"MALE","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":8},"locations":{"siteCount":5,"countries":["United States","Austria","Italy"]},"refs":{"pmids":["24938580"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":50},"commonTop":["Headache","Abdominal pain upper","Dyspepsia","Gastric disorder","Gastrooesophageal reflux disease"]}}